STARTREC-3 Trial

Cross-source consensus on STARTREC-3 Trial from 1 sources and 4 claims.

1 sources · 4 claims

Comparisons

STARTREC-3 is a prospective, non-randomised, non-comparative, multicentre phase II trial embedded in the STARTREC master protocol. — Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study
The trial plans to enrol 210 patients across three parallel arms. — Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study
STARTREC-3 does not include a TME control arm because patients choosing standard care receive TME outside the trial. — Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study
The protocol was approved in August 2024 and registered in the EU Clinical Trials Information System. — Can we Save the rectum by watchful waiting or transanal microsurgery following shorT-course radiotherapy and Additional local oR systemic Treatment for early-stage REctal Cancer? STARTREC-3 protocol for a non-randomised, multicentre, phase II platform study